Compare HOTH & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOTH | IRIX |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 23.0M |
| IPO Year | 2018 | 1996 |
| Metric | HOTH | IRIX |
|---|---|---|
| Price | $1.03 | $1.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 407.5K | 37.6K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.47 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $9.61 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.78 |
| 52 Week High | $2.12 | $1.65 |
| Indicator | HOTH | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 41.18 |
| Support Level | $0.99 | $1.04 |
| Resistance Level | $1.12 | $1.54 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 21.64 | 21.21 |
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.